ADA and acute lymphoblastic leukemia: Treatment with the anti-CD22 ADC inotuzumab ozogamicin in patients with relapsed/refractory CD22+ B-cell precursor ALL was also associated with a low incidence of ADA (3%), with no effect on the clearance of inotuzumab ozogamicin in ADA-positive patients [53].